Posted by Michael Wonder on 28 Jun 2026
Viridian Therapeutics announces US FDA approval and launch of Lumvoa (veligrotug-vvze) for the treatment of thyroid eye disease
26 June 2026 - First approved treatment for thyroid eye disease with labeling that includes data for both active and chronic thyrooid eye disease.
Viridian Therapeutics today announced that the US FDA has approved Lumvoa (veligrotug-vvze) for the treatment of thyroid eye disease.
